Week In Review: $1.7B Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
hh5800/iStock via Getty Images Deals and Financings Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma (OTCPK:ALPMF, TSE: 4503) to develop a novel bispecific macrophage engager, ES019, along with an unspecified program (see story). Initially, Elpiscience will receive up to $37 million, including an upfront payment and license option fees. Astellas…
